Tanespimycin (17-AAG)

Tanespimycin (17-allylamino-17-demethoxygeldanamycin, 17-AAG) is a semisynthetic benzoquinone ansamycin antibiotic derived from the natural product geldanamycin, originally isolated from Streptomyces hygroscopicus var. geldanus by DeBoer et al. in 1970, and the first heat shock protein 90 (HSP90) inhibitor to enter human clinical trials. The compound binds the N-terminal adenosine triphosphate (ATP) binding pocket of HSP90 with an IC50 of approximately 5 nanomolar, competitively displacing ATP and disrupting the chaperone cycle that stabilizes a broad panel of oncogenic client proteins. Inhibition of HSP90 by tanespimycin results in ubiquitination and proteasomal degradation of client proteins including HER2/ErbB2, AKT, RAF-1, CDK4, EGFR, MET, mutant p53, HIF-1alpha, and nuclear steroid receptors, precipitating collapse of multiple oncogenic signaling axes and inducing apoptosis, cell cycle arrest, and antiangiogenic effects in tumor cells. A pharmacologically distinctive feature of tanespimycin is its intracellular reduction by NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase) from the parent benzoquinone to a hydroquinone species (17-amino-17-demethoxygeldanamycin, 17-AG) that binds HSP90 with comparable or greater potency and accumulates intracellularly, linking NQO1 expression in tumor tissue to drug sensitivity. Tanespimycin demonstrates approximately 100-fold higher binding affinity for HSP90 derived from tumor cells compared to HSP90 from normal cells, a selectivity attributed to the predominantly multi-chaperone complex conformation of HSP90 in malignant tissue.

The compound was synthesized at the National Cancer Institute (NCI) in the early 1990s as part of a systematic effort to improve the pharmaceutical properties and reduce the hepatotoxicity of geldanamycin. Kosan Biosciences developed a Cremophor-based clinical formulation (KOS-953) and advanced tanespimycin through Phase I and Phase II trials in multiple tumor types, including multiple myeloma, HER2-positive breast cancer, melanoma, prostate cancer, and renal cell carcinoma. Bristol-Myers Squibb acquired Kosan Biosciences in 2008 and advanced tanespimycin to Phase III clinical development in combination with bortezomib for relapsed and refractory multiple myeloma. In a Phase II trial of tanespimycin plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab, the combination produced a 22 percent overall response rate and a 59 percent clinical benefit rate, with median progression-free survival of 6 months. In a Phase Ib/II study of tanespimycin plus bortezomib in relapsed and refractory multiple myeloma, overall response rates reached 48 percent in bortezomib-naive patients. Bristol-Myers Squibb halted all tanespimycin development in July 2010 during late-stage clinical trials, citing patent expiration (2014) and manufacturing cost considerations rather than safety or efficacy failures.

Pharmacokinetics in humans following intravenous administration are characterized by a plasma elimination half-life of approximately 3 to 5 hours for the parent compound and approximately 6 hours for the active metabolite 17-AG, with linear kinetics observed across the dose range of 150 to 525 mg/m2. Plasma protein binding is approximately 90 percent. Metabolism is predominantly hepatic via CYP3A4, with NQO1-mediated intracellular reduction constituting a pharmacologically important biotransformation pathway. The maximum tolerated dose on the twice-weekly intermittent schedule (days 1, 4, 8, and 11 of a 21-day cycle) was established at 220 mg/m2 in Phase I studies. Dose-limiting toxicities were hepatotoxicity (transaminase elevation) and thrombocytopenia. Common adverse events across clinical trials included fatigue, nausea, diarrhea, myalgia, anemia, and constipation. Tanespimycin received orphan drug designation in the United States and Europe for multiple myeloma. The compound is not approved by any regulatory authority and is available exclusively as a research-grade preparation. This monograph reviews the chemistry, synthesis, and structural pharmacology of tanespimycin; the HSP90 chaperone mechanism and client protein biology; the comprehensive human pharmacokinetic record; the preclinical and clinical evidence base across oncology indications; formulation, sourcing, and handling considerations; combination and stack interactions; the adverse-event and safety profile; and a comparative assessment of five HSP90 inhibitors (alvespimycin, ganetespib, luminespib, retaspimycin, pimitespib) against tanespimycin on five competency standards.